GlassScriptPhysician profile
Ashlee M Waugh
NPI 1831308899
$14,631.31
in general payments reported to CMS, 2019-2025
74 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $1,213 · 2021: $1,337 · 2022: $1,325 · 2023: $6,665 · 2024: $1,691 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $4,880 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $4,879.86 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $5,000.00 | 2023 | |
| Abbvie INC. | $2,076.53 | 2019-2025 | Vraylar, Qulipta, Botox |
| Novo Nordisk INC | $767.35 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $630.48 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $591.75 | 2020-2025 | Rexulti |
| Ibsa Pharma INC. | $421.72 | 2019-2025 | Tirosint, Licart, Tirosint |
| Axsome Therapeutics, INC. | $393.46 | 2022-2025 | Auvelity, Symbravo |
| Pfizer INC. | $278.16 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.94 | 2019-2025 | Trintellix |
| Lundbeck LLC | $245.16 | 2023-2025 | Rexulti, Vyepti |
| Amneal Pharmaceuticals LLC | $235.04 | 2024-2025 | Unithroid |
| Glaxosmithkline, LLC. | $205.74 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Radius Health, INC. | $178.52 | 2021-2025 | Tymlos |
| Allergan, INC. | $165.99 | 2019-2020 | |
| Amgen INC. | $164.63 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Waugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.